Kidney stones and gallstones may increase the risk for prostate cancer, which could have implications for disease monitoring and prevention in specific populations. Patients with kidney stones or ...

In 2023, 35.6% of patients received androgen-deprivation therapy alone. Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with metastatic hormone ...

In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Risk for death significantly lower for patients with return of serum testosterone to normal range value. (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a ...

Risk for death higher for individuals with hospital-based care for alcohol, stimulant, opioids versus cannabis use disorder. (HealthDay News) — Individuals who require hospital-based care for ...

The odds of major perioperative bleeding were increased 18.1-fold for patients who underwent emergent hepatic surgery, 10.9-fold for emergent splenic surgery, and 9.6-fold for emergent pancreatic ...

About 44% of respondents said they were willing to participate in a clinical trial. In a survey, less than half of cancer patients and their family members said they were willing to participate in ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...

Darolutamide plus ADT vs placebo plus ADT improves oncologic outcomes in patients with mHSPC regardless of disease volume, although the benefit is more pronounced among patients with low-volume ...

Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...